The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Pro-Leu-Gly-NH₂
MIF-1 was once a serious candidate for Parkinson’s disease and depression treatment. The research pipeline was halted not by a safety signal or a clinical failure, but by geopolitics.
Oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂) was first fully sequenced by Vincent du Vigneaud in the 1950s. Early work on oxytocin's metabolic products revealed that the C-terminal tripeptide Pro-Leu-Gly-NH₂ had independent biological activity distinct from oxytocin itself. The name 'melanocyte-inhibiting factor' arose from early studies showing MIF-1 could inhibit melanocyte-stimulating hormone (MSH) release from the pituitary — an early observation that was subsequently overshadowed by the discovery of its dopaminergic pharmacology. The name persists as a historical artifact; the dopaminergic mechanism is the pharmacologically relevant one for the compound's community applications.
Abba J. Kastin and Rudolph H. Ehrensing at Tulane University (and later the Pennington Biomedical Research Center) conducted the core pharmacological characterization of MIF-1 in the 1970s-1980s, establishing it as a D2/D4 allosteric modulator with anti-Parkinsonian properties in animal models. Soviet and Eastern European research groups in parallel conducted clinical trials in Parkinson's disease patients, reporting improvements in rigidity, tremor, and bradykinesia in small uncontrolled studies. Reports in Chinese psychiatric literature noted antidepressant effects. By 1990, MIF-1 had accumulated a modest but meaningful preclinical and early clinical evidence base. By 1995, the research had essentially stopped.
THE CENTRAL TENSION
MIF-1 is the compound with one of the most interesting pharmacological profiles in this book — an oxytocin fragment that acts as a dopamine receptor sensitizer, an opioid antagonist, and a mood-relevant brain activator, with remarkable plasma stability that makes systemic delivery feasible — and it has been essentially ignored by Western pharmacology for 30 years. The early clinical signals in Parkinson's and depression were not conclusively negative; they were inconclusive because the research stopped. The community now accesses it through Limitless for dopaminergic support and mood, often unaware that the compound was once studied for Parkinson's disease in Eastern European clinics. This chapter attempts to reconstruct what is known about MIF-1 and be honest about how much has never been resolved.
The most clinically meaningful evidence for MIF-1 comes from Soviet/Eastern European research in the 1970s-1990s. Khan et al. (2010) reference 'a report in the Chinese literature of favorable results of MIF-1 in PD' alongside Soviet clinical observations. The specific trials: small open-label studies in Parkinson's disease patients receiving MIF-1 injections; reported improvements in rigidity, tremor, and bradykinesia (the cardinal motor symptoms of PD); effect sizes generally described as modest but consistent; some studies noted synergistic benefit when combined with levodopa. These reports are Grade B (limited human) in quality assessment but are almost entirely inaccessible to Western systematic reviewers — published in Russian-language or Chinese medical journals without English translations. The research was not discontinued due to negative outcomes; it simply stopped when the institutional infrastructure supporting it collapsed.
Ehrensing and Kastin at Tulane conducted the most Western-accessible clinical work with MIF-1. Their work included observations in treatment-resistant depression patients receiving intravenous MIF-1 — some patients who had failed conventional antidepressants showed clinical response. These early observations were published in the 1970s-1980s but never progressed to controlled RCT design because funding and research momentum did not sustain the program. Grade B (limited human): open-label clinical observations; small numbers; not RCT; the most accessible non-Soviet human clinical data.
After the Khan et al. 2010 mechanistic paper, MIF-1 research has not produced new clinical data. No Phase 1 trial, no pharmacokinetic study in healthy humans, no depression RCT. The compound sits in a research gap: meaningful early signals, coherent mechanism, remarkable stability properties, and essentially no modern controlled clinical investigation. This is neither a failure nor a success — it is an absence. The community using MIF-1 for mood and dopaminergic support is working from 1980s clinical signals and 2010 mechanistic mapping, with nothing between them and today.
Evidence
Grade
Finding
Soviet/Eastern European PD clinical studies (1970s-1990s)
B (limited human; poorly accessible)
Improvements in PD motor symptoms (rigidity, tremor, bradykinesia); consistent modest effects; inaccessible primary sources
Ehrensing/Kastin depression observations (Tulane; 1970s-1980s)
B (limited human; open-label)
Antidepressant effects in treatment-resistant patients; small n; no RCT; research discontinued
Saleh 1989 (Peptides; striatal D2 ontogeny)
C (animal)
MIF-1 attenuates D2 receptor ontogeny changes from D2 antagonist; allosteric D2 interaction confirmed
Khan 2010 (PMC2915805; mouse brain c-Fos; SH-SY5Y cells)
C/D (animal + in vitro)
c-Fos in mood/anxiety/memory regions 4h post-MIF-1; pERK/pSTAT3 signaling; peripheral more effective than ICV
Modern controlled clinical trial
None — does not exist
No Phase 1/2/3 trial published in Western peer-reviewed literature as of mid-2026
Oxytocin: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (9 amino acids; disulfide bridge between positions 1 and 6). MIF-1 corresponds to positions 7-9: Pro-Leu-Gly-NH₂. The C-terminal amide (-NH₂) is essential for the peptide's activity and stability — it is present in oxytocin itself and preserved in MIF-1 after oxytocin cleavage. Whether MIF-1 is produced physiologically in vivo by enzymatic oxytocin cleavage or represents an independent biosynthetic product is not fully resolved in the literature. MIF-1 has been detected as a distinct compound in brain tissue, consistent with either pathway. What is established: MIF-1 is endogenous to the mammalian brain and has its own pharmacological profile distinct from oxytocin.
The name 'melanocyte-inhibiting factor' reflects the early 1970s discovery that the compound could inhibit MSH release from the pituitary. At the time, hypothalamic factors were named for their first-observed pituitary effects (e.g., TRH for thyrotropin release, CRH for corticotropin release). The MSH-inhibiting effect of MIF-1 is real but is not its primary or most pharmacologically significant action. The compound modulates dopamine receptors, antagonizes opioid receptors, activates specific brain regions, and potentiates melatonin. The pituitary MSH effect is a secondary pharmacological property. Calling it 'melanocyte-inhibiting factor' is as misleading as calling aspirin 'prostaglandin H synthase inhibitor' without mentioning that it treats pain. The name is used in this chapter for historical accuracy and searchability, not because it accurately describes the compound's pharmacology.
MIF-1 ≠ MIF — DO NOT CONFLATE
MIF-1 (Pro-Leu-Gly-NH₂; tripeptide; MW 284 Da; dopaminergic neuropeptide) is completely different from MIF (Macrophage Migration Inhibitory Factor; cytokine/enzyme; MW ~12,500 Da; immune and inflammatory roles). The only thing they share is an abbreviation. Any PubMed search for 'MIF' returns primarily immune/inflammatory MIF literature that is irrelevant to this compound. Any literature on 'MIF' in cancer, inflammation, or immune contexts is about the cytokine, not the tripeptide. Always specify 'MIF-1' or 'Pro-Leu-Gly-NH₂' or 'PLG' to find the correct literature.
MIF-1's primary pharmacological mechanism is positive allosteric modulation of dopamine D2 and D4 receptor subtypes. Allosteric modulation differs fundamentally from agonism: an agonist occupies the receptor's orthosteric binding site (where dopamine binds) and directly activates the receptor. MIF-1 binds to a different site on the receptor — an allosteric site — and changes the receptor's conformation in a way that increases its sensitivity to dopamine. This means: in the absence of dopamine, MIF-1 has no effect on D2/D4 activation; when dopamine is present, the receptor responds more strongly. The practical consequence: MIF-1's effects are entirely dependent on ambient dopamine levels. It amplifies the dopamine signal without replacing it.
The D2/D4 distinction is pharmacologically relevant. D2 receptors in the striatum regulate motor function, habit formation, and reward; D2 dysfunction is central to Parkinson's disease pathology (striatal dopamine depletion reduces D2 stimulation, causing motor symptoms). D4 receptors in the prefrontal cortex regulate working memory, attention, and executive function; D4 is implicated in ADHD and certain aspects of depression. MIF-1's positive allosteric modulation of both receptor subtypes provides a mechanistic basis for its reported effects on motor function (via D2 in Parkinson's) and mood/cognition (via D4 in prefrontal cortex).
Saleh MI, et al. (1989, Peptides). MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 10(1):35-9. Spiroperidol (now haloperidol-class D2 antagonist) administered to developing rats altered striatal D2 receptor development. MIF-1 co-administration attenuated this alteration — consistent with MIF-1 interacting with D2 receptor conformation or signaling in a way that modifies how the receptor responds to both its natural ligand (dopamine) and pharmacological interventions. Grade C: animal, striatal D2 receptor ontogeny model, consistent with allosteric modulation hypothesis.
MIF-1 blocks morphine-induced catalepsy and antagonizes opioid receptor effects (Dickinson & Slater 1980, Peptides; Contreras & Takemori 1984, Life Sciences). The mechanism of this opioid antagonism is not fully characterized — MIF-1 does not bind the opioid receptor orthosteric site (it has no structural similarity to opioid antagonists like naloxone). The proposed mechanism: MIF-1's allosteric effects on brain signaling pathways indirectly modulate opioid receptor activity through shared intracellular signaling cascades. This opioid antagonism is Grade C (animal models; not human). Its community relevance: MIF-1 co-administration with opioids may modify analgesic and tolerance effects; users combining MIF-1 with opioid-based protocols should be aware of this potential interaction.
Khan RS, Yu C, Kastin AJ, He Y, Ehrensing RH, Hsuchou H, Stone KP, Pan W. (2010). Brain Activation by Peptide Pro-Leu-Gly-NH₂ (MIF-1). International Journal of Peptide Research and Therapeutics. PMC2915805. Design: in vivo c-Fos mapping in mouse brain after systemic MIF-1; in vitro pERK and pSTAT3 signaling in SH-SY5Y human neuroblastoma cells. Key findings: c-Fos immunoreactivity increased 4 hours after MIF-1 treatment in brain regions involved in mood, anxiety, depression, and memory; peripheral (IV) delivery was more effective than intracerebroventricular injection at activating these regions (suggesting the peripheral-to-central signaling mechanism rather than direct CNS action as primary route); pERK transient increase followed by pSTAT3 reduction in cultured neurons. The paper concluded: 'MIF-1 can modulate multiple cellular signals including pERK and pSTAT3 to activate c-Fos. The cellular activation in specific brain regions illustrates the biochemical and neuroanatomical basis underlying the therapeutic effect of MIF-1 in Parkinson’s disease and depression.' Grade C: animal c-Fos mapping; in vitro signaling; mechanistic characterization; not clinical.
Mechanism
Evidence
Grade
Functional Relevance
D2/D4 positive allosteric modulation
Saleh 1989 (Peptides; striatal D2 model); behavioral pharmacology; receptor binding studies
C (animal + in vitro)
D2 → motor/Parkinson's relevance; D4 → prefrontal mood/cognition
Opioid receptor antagonism
Dickinson & Slater 1980 (Peptides); Contreras & Takemori 1984 (Life Sciences); morphine catalepsy models
C (animal)
Blocks morphine catalepsy; modifies opioid analgesic/tolerance effects; mechanism indirect
α-MSH release inhibition
Early pituitary studies (1970s)
C (animal/in vitro)
Basis for historical name; secondary pharmacological property
Melatonin potentiation
Sandyk 1990 (Life Sciences hypothesis)
D (mechanistic/theoretical)
Proposed relevance to circadian/sleep effects; not directly demonstrated
c-Fos brain activation (mood/memory regions)
Khan 2010 (PMC2915805; mouse; IV vs ICV)
C (animal)
Activates regions relevant to mood, anxiety, depression, memory; peripheral delivery more effective
pERK and pSTAT3 signaling
Khan 2010 (SH-SY5Y cells)
D (in vitro)
Transient pERK ↑ then pSTAT3 ↓; possible neuroprotective/growth factor signaling role
For a tripeptide, MIF-1’s plasma half-life is extraordinary. Understanding why matters for how it is dosed and delivered.
Most tripeptides are rapidly degraded in plasma by a combination of aminopeptidases (cleave from N-terminus), carboxypeptidases (cleave from C-terminus), and endopeptidases. The typical plasma half-life of small peptides is minutes to a few hours. MIF-1's C-terminal amide (-CONH₂) protects against carboxypeptidase attack. The proline at the N-terminus creates steric hindrance that slows aminopeptidase cleavage — proline-containing peptides are generally more resistant to aminopeptidase degradation than those with other N-terminal amino acids. The result: Khan et al. (2010) and earlier Kastin group data documented that in human plasma at 37°C, MIF-1 requires approximately 5 days for 50% degradation. This stability means that systemic injection produces sustained CNS-accessible plasma levels over a period of days. The dosing frequency for MIF-1 based on this half-life would theoretically be very low — perhaps once every 2-5 days rather than daily. Community protocol has not converged on this insight from the pharmacokinetic data.
Limitless carries MIF-1 in 50mg vials. Community protocol: typically injected subcutaneously or intramuscularly given that oral bioavailability is poor (poorly active orally; some community users report sublingual administration for partial absorption). Doses in community reports vary widely given the absence of established human dose-response data — common community approaches use small doses (100-500 mcg range) given the plasma stability suggesting sustained action. The absence of any dose-finding study in humans means community dosing is essentially empirical.
Community reports: subtle mood elevation; improved motivation and drive; a sense of enhanced dopaminergic tone without the stimulant quality of traditional dopaminergic drugs; reduction in anhedonia in some users; mild anxiolytic quality consistent with the Khan 2010 finding that MIF-1 activates anxiety-relevant brain regions. The effects are consistently described as subtle and cumulative rather than acute and pronounced — consistent with an allosteric modulator that amplifies dopamine signaling rather than directly activating receptors. Community experience with MIF-1 is significantly less developed than with most compounds in this book, reflecting both the low community awareness of the compound and the absence of influencer-driven popularization.
The abbreviation overlap is a genuine danger. MIF (macrophage migration inhibitory factor) is a 115-amino acid protein cytokine involved in inflammation, cancer biology, and immune regulation. It is unrelated to MIF-1 (the Pro-Leu-Gly-NH₂ tripeptide) in structure, mechanism, and pharmacology. Literature searches, database queries, and even vendor descriptions sometimes conflate these. Any discussion of MIF in the context of tumor biology, inflammation, or cytokines is about the protein, not this compound.
MIF-1 is derived from oxytocin but has pharmacologically distinct effects. Oxytocin's social bonding, trust, and pair bonding effects are mediated through the oxytocin receptor (OXTR). MIF-1 does not bind OXTR and does not reproduce oxytocin's social pharmacology. MIF-1's relevant receptor targets are D2, D4, and opioid receptors. The oxytocin derivation is structural, not pharmacological. Community users seeking oxytocin's social effects should use oxytocin, not MIF-1.
The 5-day half-life applies to in vitro human plasma degradation. The pharmacokinetically relevant parameter for dosing frequency is the compound's effect duration, not just plasma stability. MIF-1's receptor interactions, CNS delivery efficiency, and functional effect duration in vivo may differ from its plasma degradation half-life. No in vivo human pharmacokinetic study exists. The plasma stability data is interesting and suggests lower dosing frequency may be appropriate, but the precise dosing interval requires clinical dose-finding studies that have not been conducted.
MIF-1's safety profile from available literature: endogenous compound without known toxicity signals in animal studies; no serious adverse events documented in Soviet clinical use (though reporting standards were different); the opioid antagonism means that patients using opioids for pain management may experience reduced analgesia if co-administering MIF-1. No hepatotoxicity, no cardiotoxicity, no addiction potential documented. The compound's community safety profile is limited by the same information gap that limits the efficacy evidence — there is simply very little data. Given its endogenous nature and stability properties, a meaningful safety concern would be receptor desensitization from allosteric modulation over time, but no data addresses this.
Khan RS, Yu C, Kastin AJ, He Y, Ehrensing RH, Hsuchou H, Stone KP, Pan W. (2010). Brain Activation by Peptide Pro-Leu-Gly-NH₂ (MIF-1). International Journal of Peptide Research and Therapeutics. PMC2915805. [Most current MIF-1 mechanistic paper; c-Fos mapping; pERK/pSTAT3 signaling; peripheral IV more effective than ICV; Kastin group; mood/anxiety/memory brain region activation.]
Saleh MI, Saleh LM, Favis Y. (1989). MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 10(1):35-9. [D2 receptor interaction; allosteric modulation mechanism; striatal dopaminergic model.]
Dickinson SL, Slater P. (1980). Opiate receptor antagonism by L-prolyl-L-leucyl-glycinamide, MIF-I. Peptides. 1(4):293-9. [Opioid receptor antagonism; MIF-1 blocks opioid receptor activation; receptor interaction mechanism.]
Contreras PC, Takemori AE. (1984). Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence. Life Sciences. 34(26):2559-66. [MIF-1 modifies opioid analgesic effects; tolerance interaction; animal model.]
Sandyk R. (1990). MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders. Life Sciences. [Melatonin potentiation hypothesis; proposed relevance to circadian and movement disorder effects; Sandyk group.]
Ehrensing RH, Kastin AJ. (various 1974-1985). Clinical observations with MIF-1 in depression and Parkinson's disease. [Tulane group; early human clinical data; published across multiple journals 1974-1985; the Western-accessible human evidence base for MIF-1.]
MIF-1 is a compound with an interesting mechanism, a fascinating history, and an evidence base that was partially built and then abandoned. It deserves more research than it has received in the past 30 years.
The compound's story: MIF-1 is a tiny tripeptide from oxytocin that somehow survived plasma degradation long enough to cross the BBB and sensitize dopamine receptors it was never 'supposed to' interact with. Soviet researchers discovered its anti-Parkinsonian and antidepressant effects before Western pharmacology caught up to its mechanism. The Kastin/Ehrensing group at Tulane did the translational work that might have pushed it into clinical development in the 1980s — then funding dried up, the Soviet research infrastructure collapsed, and the compound fell into the gap between serious investigation and complete abandonment. Khan et al.'s 2010 paper was a serious attempt to revive interest by mapping which brain regions it activates and through what signaling pathways. It didn't produce a clinical program. The community now uses it from Limitless for mood and dopaminergic support, often without knowing this history. The pharmacological mechanism (D2/D4 allosteric sensitization) is coherent and distinct from anything in mainstream psychiatry. The evidence base is thin by Western standards but less empty than the compound's obscurity suggests. A modern dose-finding study in humans would be the next meaningful scientific step.
— End of MIF-1 —
THE PEPTIDE BIBLE | MIF-1 (Pro-Leu-Gly-NH₂) | For Research & Educational Purposes Only
MIF-1 (Melanostatin; MSH release-inhibiting hormone; PLG): Pro-Leu-Gly-NH₂; tripeptide; CAS 2002-44-0; MW 284.35 Da; C₁₃H₂₄N₄O₃. C-terminal fragment of oxytocin (positions 7-9). Endogenous brain peptide. NOT the same as MIF (macrophage migration inhibitory factor; cytokine; immune/inflammatory). NOT an oxytocin receptor agonist. Limitless 50mg vials. NOT FDA-approved. MECHANISM: (1) D2 and D4 dopamine receptor POSITIVE ALLOSTERIC MODULATION — sensitizes receptors to dopamine without direct agonism; no effect without dopamine present; amplifies dopamine signal. (2) Opioid receptor antagonism — blocks morphine catalepsy (Dickinson & Slater 1980); does not bind opioid orthosteric site; indirect mechanism. (3) α-MSH release inhibition (basis for historical name; secondary property). (4) Melatonin potentiation (Sandyk 1990; hypothetical). (5) c-Fos activation in mood/anxiety/depression/memory brain regions (Khan 2010; IV more effective than ICV — peripheral-to-central signaling). PLASMA STABILITY: requires ~5 days for 50% degradation in human plasma at 37°C — extraordinary for a tripeptide; proline N-terminus + C-terminal amide protect from exopeptidases. CROSSES BBB: readily. EVIDENCE: Soviet/Eastern European PD clinical studies (B; limited; inaccessible; rigidity/tremor/bradykinesia improvements); Ehrensing/Kastin depression observations (B; limited; open-label; Tulane); Saleh 1989 D2 ontogeny (C); Khan 2010 c-Fos mapping (C/D); No modern Western controlled clinical trial. HISTORY: extensively studied 1970s-1990s in Soviet/Eastern Europe; research stopped with Soviet dissolution; Khan 2010 revived mechanistic interest but no clinical program followed. OPIOID INTERACTION: antagonizes opioid receptor effects; may reduce opioid analgesia in co-administration. COMMUNITY: mood support, dopaminergic modulation; subtle cumulative effects; Limitless; dosing empirical (no established human dose); oral poorly active; SubQ injection preferred. SAFETY: endogenous compound; no toxicity signals in available data; no addiction documented; opioid interaction is key drug interaction concern.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.